



ADULT

TENOFOVIR with EMTRICITABINE (Truvada®)




This document should be read in conjunction with this [DISCLAIMER](#)

[Antimicrobial Restriction – Restricted \(IV\)](#)

HIGH RISK Medication 

Presentation	Tablet: Tenofovir 300mg with Emtricitabine 200mg
Dose	<p><u>Post exposure prophylaxis (PEP)</u></p> <p>Oral: ONE tablet daily Starter pack is available in EC and SARC. A 28 day course of PEP is recommended</p> <p><u>Post exposure prophylaxis (PEP) in minors >35kg</u></p> <p>Oral: ONE tablet daily PLUS Raltegravir Total 28 day course available in SARC</p>
Administration	Where PEP is recommended, it should be prescribed and started as soon as possible after the exposure and within 72 hours
Pregnancy	<p>1st Trimester: Considered safe to use 2nd Trimester: Considered safe to use 3rd Trimester: Considered safe to use</p>
Breastfeeding	<p>This medication is contraindicated due to potential HIV transmission not based on the risk of the medication to the infant via breastmilk</p> <p>Use a safe alternative method to breastfeeding to avoid postnatal HIV transmission</p> <p>Small amounts of tenofovir and emtricitabine are transferred into breastmilk which have not resulted in significant infant exposure</p>
Monitoring	BMD and renal function

<p>Clinical guidelines and Policies</p>	<p>WNHS Policy: Antimicrobial Stewardship at KEMH Management of exposures to blood and body fluid HIV Positive: Management of the woman and her Neonate Post-Exposure Prophylaxis after Non-Occupational and Occupational exposure to HIV Australian national Guidelines(second edition 2016)</p>
<p>References</p>	<p>Australian Medicines Handbook. Tenofovir. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2017 [cited 2018 Jan 13]. Available from: https://amhonline.amh.net.au/</p> <p>Therapeutic Guidelines. Postexposure prophylaxis against bloodborne viruses. In: eTG complete [Internet]. West Melbourne (Victoria): Therapeutic Guidelines; 2017 [cited 2018 Jan 13]. Available from: https://tgldcdp.tg.org.au</p> <p>The Royal Women's Hospital. Tenofovir. In: Pregnancy and Breastfeeding Medicines Guide [Internet]. Parkville (Victoria): The Royal Women's Hospital; 2016 [cited 2018 Jan 13]. Available from: https://thewomenspbmg.org.au/</p> <p>Hale TW. Emtricitabine. In: Medications and Mothers' Milk [Internet]. New York: Springer Publishing Company; 2017 [cited 2018 Jan 13]. Available from: http://www.medsmilk.com</p> <p>Hale TW. Tenofovir. In: Medications and Mothers' Milk [Internet]. New York: Springer Publishing Company; 2017 [cited 2018 Jan 13]. Available from: http://www.medsmilk.com</p>

Keywords:	HIV, truvada, tenofovir, emtricitabine, post exposure prophylaxis, PEP		
Publishing:	<input checked="" type="checkbox"/> Intranet <input checked="" type="checkbox"/> Internet		
Document owner:	Chief Pharmacist		
Author / Reviewer:	KEMH Pharmacy Department		
Date first issued:	July 2015	Version:	3.1
Last reviewed:	January 2018	Next review date:	Jan 2021
Endorsed by:	Medicines and Therapeutics Committee	Date:	Jan 2018
Standards Applicable:	NSQHS Standards: 1  Clinical Care is Guided by Current Best Practice 3  Infection Control 4  Medication Safety		
Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from the WNHS website.			

© Department of Health Western Australia 2018